2TK Stock Overview
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Eledon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$2.64 |
| 52 Week Low | US$1.00 |
| Beta | 0.93 |
| 1 Month Change | 32.08% |
| 3 Month Change | 33.76% |
| 1 Year Change | -7.08% |
| 3 Year Change | -72.37% |
| 5 Year Change | -94.33% |
| Change since IPO | -97.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2TK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.5% | 2.1% | -1.0% |
| 1Y | -7.1% | -22.4% | 2.0% |
Return vs Industry: 2TK exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 2TK underperformed the German Market which returned 2% over the past year.
Price Volatility
| 2TK volatility | |
|---|---|
| 2TK Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2TK's share price has been volatile over the past 3 months.
Volatility Over Time: 2TK's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | DA Gros | eledon.com |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
Eledon Pharmaceuticals, Inc. Fundamentals Summary
| 2TK fundamental statistics | |
|---|---|
| Market cap | €55.55m |
| Earnings (TTM) | -€37.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 2TK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2TK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.33m |
| Earnings | -US$40.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2TK perform over the long term?
See historical performance and comparison